Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7560359 | 0.86 | THRA (0.37) | CA1CA2TAAR1 | |
| SCHEMBL3739374 | 0.79 | TSHR (0.39) | TAAR1 | |
| SCHEMBL25828304 | 0.78 | — | — | |
| SCHEMBL7105339 | 0.76 | ESR1 (0.59) | CA2TAAR1 | |
| SCHEMBL13658160 | 0.76 | GFER (0.47) | CA1CA2TAAR1 | |
| SCHEMBL7519038 | 0.76 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL476138 | 0.75 | TP53 (0.50) | TAAR1CYP2A6 | |
| SCHEMBL1325663 | 0.74 | KCNH2 (0.50) | — | |
| Methane SCHEMBL17138226 | 0.73 | GFER (0.45) | CA1CA2TAAR1 | |
| SCHEMBL97582 | 0.72 | CA1 (0.52) | CA1CA2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825103-B2 | 5'-O-triisopropylsilyl-2'-cyano-2'-deoxy-1- beta -D-arabinofuranosylcytosine; antitumor agents | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-7771740-B2 | Medical devices containing copolymers with graft copolymer endblocks for drug delivery | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090118222-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1845102-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1771218-A2 | MEDICAL DEVICES CONTAINING COPOLYMERS WITH GRAFT COPOLYMER ENDBLOCKS FOR DRUG DELIVERY | Boston Scientific Scimed, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1179566-B1 | ELASTOMER COMPOSITION AND THERMOPLASTIC RESIN COMPOSITION CONTAINING THE SAME | KANEKA CORP (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006014606-A2 | MEDICAL DEVICES CONTAINING COPOLYMERS WITH GRAFT COPOLYMER ENDBLOCKS FOR DRUG DELIVERY | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060013854-A1 | Medical devices containing copolymers with graft copolymer endblocks for drug delivery | BOSTON SCIENTIFIC SCIMED, INC. | 2006-01-19 | — | — | US | disclosed |
| US-6534594-B1 | Methacrylate-siloxane block copolymer; impact strength | KANEKA CORPORATION (JP) | 2003-03-18 | — | — | US | disclosed |
| EP-1179566-A1 | ELASTOMER COMPOSITION AND THERMOPLASTIC RESIN COMPOSITION CONTAINING THE SAME | KANEKA CORPORATION (JP) | 2002-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118222-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | CDK10, SRSF9, SNRPD1 | CA1 1686/4885CA2 1991/4885TAAR1 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.